Charles M. Baum
2017
In 2017, Charles M. Baum earned a total compensation of $1.6M as President and Chief Executive Officer at Mirati Therapeutics, a 45% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $225,100 |
|---|---|
| Option Awards | $831,701 |
| Salary | $562,800 |
| Other | $2,920 |
| Total | $1,622,521 |
Baum received $831.7K in option awards, accounting for 51% of the total pay in 2017.
Baum also received $225.1K in non-equity incentive plan, $562.8K in salary and $2.9K in other compensation.
Rankings
In 2017, Charles M. Baum's compensation ranked 6,578th out of 14,666 executives tracked by ExecPay. In other words, Baum earned more than 55.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,578 out of 14,666 | 55th |
Division Manufacturing | 2,433 out of 5,768 | 58th |
Major group Chemicals And Allied Products | 781 out of 2,074 | 62nd |
Industry group Drugs | 603 out of 1,730 | 65th |
Industry Pharmaceutical Preparations | 476 out of 1,329 | 64th |
Source: SEC filing on April 20, 2018.
Baum's colleagues
We found four more compensation records of executives who worked with Charles M. Baum at Mirati Therapeutics in 2017.
2017
Isan Chen
Mirati Therapeutics
Executive Vice President and Chief Medical and Development Officer
2017
James Christensen
Mirati Therapeutics
Chief Scientific Officer
2017
Jamie Donadio
Mirati Therapeutics
Chief Financial Officer
2017
Chris LeMasters
Mirati Therapeutics